wtf is going with HISTOGEN phase 2b?

[Desmond84]

Guys we're 4 days from Dec 2013. It's now 12 months since Phase 1/2a ended. Histogen has not announced any news about their estimated date for initiation of Phase 2b. There is no draft protocol either. Their merger deal fell through as well.

How do you guys feel? Will 2014 be just like 2013? Apart from attending conferences all operations on Hair stimulating complex have halted!

I wish we didn't even know about Histogen...that way we wouldn't be so disappointed in not being able to use it, even though the science is solid and efficacy is proven

Thinning87 I know you hate it when I make these posts BUT I had to...getting so tired of waiting when we are still where we were exactly 12 months ago!

[Hairismylife]

Guys we're 4 days from Dec 2013. It's now 12 months since Phase 1/2a ended. Histogen has not announced any news about their estimated date for initiation of Phase 2b. There is no draft protocol either. Their merger deal fell through as well.

How do you guys feel? Will 2014 be just like 2013? Apart from attending conferences all operations on Hair stimulating complex have halted!

I wish we didn't even know about Histogen...that way we wouldn't be so disappointed in not being able to use it, even though the science is solid and efficacy is proven

Thinning87 I know you hate it when I make these posts BUT I had to...getting so tired of waiting when we are still where we were exactly 12 months ago!

We still have CB!
Only correct vehicle needed to be found out.

[yeahyeahyeah]

Guys we're 4 days from Dec 2013. It's now 12 months since Phase 1/2a ended. Histogen has not announced any news about their estimated date for initiation of Phase 2b. There is no draft protocol either. Their merger deal fell through as well.

How do you guys feel? Will 2014 be just like 2013? Apart from attending conferences all operations on Hair stimulating complex have halted!

I wish we didn't even know about Histogen...that way we wouldn't be so disappointed in not being able to use it, even though the science is solid and efficacy is proven

Thinning87 I know you hate it when I make these posts BUT I had to...getting so tired of waiting when we are still where we were exactly 12 months ago!

They just had a merger with another company, I am sure they are busy with a lot of paper work atm.

[Javert]

They just had a merger with another company, I am sure they are busy with a lot of paper work atm.

Really?

[yeahyeahyeah]

Really?

Stratus Media Group and Histogen Execute Letter of Intent for Biotechnology Merger

LOS ANGELES, October 07, 2013 - Stratus Media Group, Inc. (OTCQB:SMDI) announced today that it was planning to expand its entrance into the biotechnology industry with the execution of a letter of intent between the Company and Histogen, Inc., a regenerative medicine company developing innovative therapies for conditions including hair loss and cancer.
The non-binding letter of intent outlines the primary terms of a merger of San Diego-based Histogen into Stratus, to be renamed Restorgenex Corporation. The letter of intent has been approved by the board of directors of both companies, and the parties are engaged in completing a formal merger agreement.
Histogen's solutions are based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. The technology focuses on stimulating a patient's own stem cells by delivering a proprietary complex of proteins that have been shown to support stem cell growth and differentiation. Histogen's lead product, Hair Stimulating Complex (HSC) has shown success in two Company-sponsored clinical trials as an injectable treatment for alopecia. In addition, the human multipotent cell conditioned media produced through Histogen's process can be found in skincare products including ReGenica, which is distributed by Suneva Medical in partnership with Obagi Medical Products.
"Histogen's technology platform opens a spectrum of potential product opportunities in both aesthetics and therapeutics, an ideal fit with our vision for Restorgenex," said Sol J. Barer, Ph.D., who will assume the position of Chairman of the Board of Restorgenex effective November 1, 2013. "The expertise of the Histogen team in developing regenerative products from concept to market, along with the success Histogen has already found in skincare partnering, will add significant value to our Company."

Following successful completion of this proposed merger, the company's goal is to build Restorgenex into a world-class cosmeceutical and pharmaceutical company in the large and expanding fields of dermatology and hair restoration. The parties intend to move toward a formal merger agreement in which Histogen would become a wholly-owned subsidiary, Histogen founder Gail K. Naughton, Ph.D. would assume the position of Chief Executive Officer of Restorgenex, and the corporate headquarters of Restorgenex would be located in San Diego. The merger will require, among other things, the satisfaction of customary closing conditions including the approval of Histogen's shareholders.
"I am very excited about the potential of a merger between Histogen and Restorgenex, and look forward to moving into the next stage," said Dr. Naughton. "It is an honor to be working with biotechnology visionaries Dr. Sol Barer and Isaac Blech, and to have them recognize the promise of Histogen's products is a true testament to the unique and exciting nature of our technology."

Dr. Naughton has spent more than 25 years extensively researching the tissue engineering process, holds more than 95 U.S. and foreign patents, and has been honored for her pioneering work in the field by prestigious organizations including receiving the Intellectual Property Owners Association Inventor of the Year Award.
Prior to founding Histogen in 2007, Dr. Naughton oversaw the design and development of the world's first up-scaled manufacturing facility for tissue engineered products, was pivotal in raising over $350M from the public market and corporate partnerships, and brought four human cell-based products from concept through FDA approval and market launch as President of Advanced Tissue Sciences.
"I believe the potential acquisition of Histogen, and the expertise and vision Dr. Naughton will bring as Chief Executive Officer will be a tremendous asset in ushering the Company into the biotechnology industry," said Jerold Rubinstein, current Chairman and Chief Executive Officer of Stratus.

https://www.histogen.com

https://www.stratusmediagroup.com

October the 7th.

The reason why there could be a delay, because they now need to figure out the best way forward. Business plan etc.

[FearTheLoss]

October the 7th.

The reason why there could be a delay, because they now need to figure out the best way forward. Business plan etc.

Yes, but then this company recently dropped them.

[yeahyeahyeah]

Yes, but then this company recently dropped them.

Source?

[Duke]

Source?

http://www.baldtruthtalk.com/showthread.php?t=14785&page=3

[crafter]

if Histo have lost funding then that will set them back at least 2 years, depending on if they find a backer, or they'll just go same way as Aderans

[Thinning87]

Guys we're 4 days from Dec 2013. It's now 12 months since Phase 1/2a ended. Histogen has not announced any news about their estimated date for initiation of Phase 2b. There is no draft protocol either. Their merger deal fell through as well.

How do you guys feel? Will 2014 be just like 2013? Apart from attending conferences all operations on Hair stimulating complex have halted!

I wish we didn't even know about Histogen...that way we wouldn't be so disappointed in not being able to use it, even though the science is solid and efficacy is proven

Thinning87 I know you hate it when I make these posts BUT I had to...getting so tired of waiting when we are still where we were exactly 12 months ago!

Well even if we all told you we feel the same way, what difference would it make? I have no doubts they are working on this as hard as they can. Things hardly ever go as planned and histogen is no exception.

[baldingatseventeen]

I'm a little confused.

As stated previously, this was intended to be a reverse takeover between Histogen and Stratus. To my understanding, a reverse takeover occurs when a smaller company on the rise wants to enter the stock market without all the bureaucracy of securing an IPO.

I understand that this means Histogen won't be able to attract public funding for now but how does this in any way mean that the company is shutting down, or even losing investment money in the long run? I don't see why this couldn't have simply been a bureaucratic problem or disagreement with Stratus (the company that Histogen is effectively taking over, NOT receiving investment from). Some of the posts here seem to indicate that people think Stratus was investing in Histogen.

Those of you know more than me, do you know for certain that Histogen being unable to secure public funding from stock options will hinder the company's development? If so, how much of an impact do you think it will have?

Perhaps it was Histogen who decided to call off the merger because they decided an alternative business plan was better?

[HairBane]

I'm a little confused.

As stated previously, this was intended to be a reverse takeover between Histogen and Stratus. To my understanding, a reverse takeover occurs when a smaller company on the rise wants to enter the stock market without all the bureaucracy of securing an IPO.

I understand that this means Histogen won't be able to attract public funding for now but how does this in any way mean that the company is shutting down, or even losing investment money in the long run? I don't see why this couldn't have simply been a bureaucratic problem or disagreement with Stratus (the company that Histogen is effectively taking over, NOT receiving investment from). Some of the posts here seem to indicate that people think Stratus was investing in Histogen.

Those of you know more than me, do you know for certain that Histogen being unable to secure public funding from stock options will hinder the company's development? If so, how much of an impact do you think it will have?

Perhaps it was Histogen who decided to call off the merger because they decided an alternative business plan was better?

The CEO has said before that they need more funding. I think the reason people are worried is because a reverse merger can be misconstrued as a desperate move for companies that can't afford to get funding via other means.

[Vox]

The CEO has said before that they need more funding. I think the reason people are worried is because a reverse merger can be misconstrued as a desperate move for companies that can't afford to get funding via other means.

Here it is clearly stated:

The greater number of financing options available to publicly held companies is a primary reason to undergo a reverse takeover.

As per their CEO, it is not a secret that Histogen has trouble to get the appropriate funds to pursue research. Their reverse merge attempt should be considered in this light, although it does not imply that they are shutting anything down for the moment. But delays are very likely to occur.

[huawei]

She'll be right.

The reality is that stratus are more or less dead in the water. Histogen have other things going on as well, not just their HSC, so funding will come in time.

[HairBane]

She'll be right.

The reality is that stratus are more or less dead in the water. Histogen have other things going on as well, not just their HSC, so funding will come in time.

Aderans had a lot of technology too, but they shut down due to financial issues. That said, the fact that Histogen are maybe only 1 trial away from making some money with their product in Asia means that Gail will do whatever it takes to see it through. She's very experienced with this sort of thing from what I've heard - and HSC is the best near-term solution to early MPB I've seen.